Metformin Use and the Outcome of Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F21%3AN0000117" target="_blank" >RIV/00064190:_____/21:N0000117 - isvavai.cz</a>
Alternative codes found
RIV/00669806:_____/21:10429442 RIV/00216208:11140/21:10429442 RIV/00216208:11110/21:10429442
Result on the web
<a href="http://dx.doi.org/10.2147/CMAR.S305321" target="_blank" >http://dx.doi.org/10.2147/CMAR.S305321</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2147/CMAR.S305321" target="_blank" >10.2147/CMAR.S305321</a>
Alternative languages
Result language
angličtina
Original language name
Metformin Use and the Outcome of Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib
Original language description
Background: The anticancer properties of metformin have been suggested in numerous experimental studies and several retrospective clinical studies show that its use is associated with improved outcome of patients with cancer. However, limited data are available for patients with metastatic renal cell carcinoma (mRCC) treated with targeted therapy. The aim of this retrospective study was to assess the impact of the metformin use on survival of mRCC patients treated with sunitinib or pazopanib. Methods: Clinical data from 343 patients with mRCC treated with sunitinib or pazopanib in the first line were analyzed. Progression-free survival (PFS) and overall survival (OS) were compared according to the use of metformin. Results: The median PFS and OS for patients using metformin was 31.1 (95% CI 20.6-35.1) and 51.6 (95% CI 44.7-NR) months compared to 9.3 (95% CI 8.0-12.0) and 22.4 (95% CI 19.4-26.8) months for patients not using metformin (p<0.0001 and p=0.0002, respectively). Cox multivariate analysis shows that the use of metformin remains a significant factor for PFS (HR=0.55 [95% CI 0.343-0.883], p= 0 .013) and also for OS (HR=0.45 [95% CI 0.256-0.794], p=0.006). Conclusion: The present study results suggest that the use of metformin was associated with favorable outcome of mRCC patients treated with sunitinib or pazopanib.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
CANCER MANAGEMENT AND RESEARCH
ISSN
1179-1322
e-ISSN
—
Volume of the periodical
13
Issue of the periodical within the volume
2021
Country of publishing house
NZ - NEW ZEALAND
Number of pages
10
Pages from-to
4077-4086
UT code for WoS article
000653193800001
EID of the result in the Scopus database
2-s2.0-85107436620